Consensus Avalo Therapeutics, Inc.

Stocks

AVTX

US05338F3064

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-07-02 EDT			5-day change	1st Jan Change
18.84 ^USD	+8.96%		+3.74%	+3.74%

06-16	Avalo Therapeutics Plans IND Application for AVTX-010 in H1 2027	MT
06-16	Avalo Therapeutics Expands Pipeline with AVTX-010, A Long-Acting Next-Generation Anti-Il-1? Antibody	CI

Evolution of the Average Target: Avalo Therapeutics, Inc.

Evolution of the Target Price: Avalo Therapeutics, Inc.

Changes in Analyst Recommendations: Avalo Therapeutics, Inc.

9ea76e8ecdfd7d89.j6KUofOB7QF2xC4ZEnZLjyz-tqCpH-DpxwAe0MTV6Y4.7tSl14Oz2DZGskohQgwC1na0gtDhetGKs2EtqJaApOXB99jIo7KodU_wfw~69a20f393bf09ff7d114fc44e78c2e5c

Analysts' recommendations: Avalo Therapeutics, Inc.

06-12	Avalo Therapeutics' Lead Drug now a Cleaner Immunology Story, BofA Says	MT
06-12	BofA Initiates Avalo Therapeutics at Buy With $35 Price Target	MT
05-14	Mizuho Adjusts Price Target on Avalo Therapeutics to $45 From $39, Maintains Outperform Rating	MT
05-14	Wedbush Adjusts Price Target on Avalo Therapeutics to $34 From $40, Maintains Outperform Rating	MT
05-06	Wedbush Adjusts Price Target on Avalo Therapeutics to $40 From $29, Maintains Outperform Rating	MT
03-24	Wedbush Raises Price Target on Avalo Therapeutics to $29 From $28, Keeps Outperform Rating	MT
02-02	Guggenheim Initiates Coverage on Avalo Therapeutics With Buy Rating, $50 Price Target	MT
12-18	Mizuho Initiates Avalo Therapeutics at Outperform With $39 Price Target	MT
25-09-05	TD Cowen Initiates Avalo Therapeutics at Buy	MT
25-08-15	Cantor Fitzgerald Initiates Avalo Therapeutics at Overweight	MT
25-03-25	Stifel Initiates Avalo Therapeutics at Buy With $36 Price Target	MT
25-02-28	Piper Sandler Initiates Avalo Therapeutics at Overweight With $48 Price Target	MT
25-02-21	Wedbush Initiates Avalo Therapeutics With Outperform Rating, $18 Price Target	MT
24-12-19	BTIG Research Initiates Avalo Therapeutics With Buy Rating, $40 Price Target	MT
24-10-24	HC Wainwright Initiates Avalo Therapeutics at Neutral	MT
24-04-16	Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35	MT
23-06-27	Oppenheimer Downgrades Avalo Therapeutics to Perform From Outperform, Removes $10 Price Target	MT
23-06-27	Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept	MT
23-05-10	RBC Cuts Price Target on Avalo Therapeutics to $9 From $17, Maintains Outperform Rating, Speculative Risk Qualifier	MT
23-02-08	Jefferies Downgrades Avalo Therapeutics to Underperform From Hold, Lowers Price Target to $3 From $4.50	MT
22-11-09	Oppenheimer Adjusts Avalo Therapeutics Price Target to $10 From $17, Maintains Outperform Rating	MT
22-08-08	Oppenheimer Adjusts Avalo Therapeutics Price Target to $17 From $5, Maintains Outperform Rating	MT
22-08-05	RBC Cuts Price Target on Avalo Therapeutics to $17 From $21, Maintains Outperform Rating, Speculative Risk Qualifier	MT
22-07-11	RBC Cuts Price Target on Avalo Therapeutics to $21 From $24 After 1-for-12 Reverse Stock Split; Outperform, Speculative Risk Kept	MT
22-05-06	RBC Halves Price Target on Avalo Therapeutics to $2 From $4, Noting 'Early Stage Risk With Minimal Safeguards,' Keeps Outperform-Speculative Risk Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	AVALO THERAPEUTICS, INC.					+161.71%
	ARGENX SE					+10.28%
	WUXI APPTEC CO., LTD.					+16.98%
	BIONTECH SE					+31.88%
	INSMED INCORPORATED					+84.16%
	WUXI BIOLOGICS (CAYMAN) INC.					+35.46%
	GENMAB A/S					+28.51%
	PHARMAESSENTIA CORPORATION					-33.36%
	EXELIXIS, INC.					-8.27%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+25.55%
	Average					+35.29%
	Weighted average by Cap.					+21.91%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

18.84USD

Average target price

45.25USD

Spread / Average Target

+140.18%

High Price Target

60.00USD

Spread / Highest target

+218.47%

Low Price Target

34.00USD

Spread / Lowest Target

+80.47%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

BofA Securities
Wedbush
Mizuho Securities
Guggenheim
TD Cowen
Cantor Fitzgerald
Stifel Nicolaus
Piper Sandler
BTIG
HC Wainwright
Oppenheimer
RBC Capital Markets
Jefferies & Co.
Maxim